City of Hope is First to Offer a Novel Precision Medicine Technology in Southern California

PET scan | Image Credit: © Gorodenkoff - www.stock.adobe.com

The RefleXion® X1 system, a targeted radiation therapy, is now available at City of Hope. As a result, City of Hope has become the first cancer center in Southern California to offer this treatment to patients.¹

The RefleXion X1 system transports SCINTIX biology-guided radiotherapy. It is a PET radiation therapy technology, which illuminates tumors on PET to track cancer cells in real time.

Based on the FDA marketing authorization granted for the RefleXion X1 system in February 2023, patients with primary or metastatic lung and bone cancer are eligible to undergo the treatment. Previously, the system received breakthrough device designation from the FDA.²

It is City of Hope’s belief that RefleXion X1 may be able to treat other tumors in the future.

“City of Hope is committed to finding more effective treatments with fewer [adverse] effects for our patients, and being one of the first cancer systems in the nation to offer this groundbreaking technology aligns strongly with our mission,” said Terence Williams, MD, PhD, professor and chair of the Department of Radiation Oncology at City of Hope, in a press release.1 “Lung and bone cancer patients with metastatic disease now have an option with the potential to target more tumors with fewer [adverse] effects by minimizing damage to healthy cells, both critical factors in patients with advanced disease.”

Administration of RefleXion X1 is a part of multiple ongoing studies at City of Hope, which utilize the precision medicine technology. In 1 study of patients with various cancers, 500 patients will be treated with either body radiotherapy via RefleXion X1 of or modulation radiation therapy via RefleXion X1 (NCT05406167). Patients included can have either central nervous system caner, thoracic cancer, gastrointestinal cancer, gynecologic cancer, genitourinary cancer, lymphatic cancer, or head and neck cancer.

The primary end point of the study is health-related quality of life (HRQOL), and the secondary end points include long-term HRQOL, acute toxicities related to radiotherapy, disease status, intervention and episodic costs, and long-term toxicities related to radiotherapy.^1,3

Patients eligible for the study are those with a diagnosis of local, locally advanced, or metastatic cancer. Patients cannot have a concurrent illness that interferes with radiotherapy, be pregnant, or have a history of psychiatric or substance abuse disorder. Patients must also be able to maintain immobilization and supine position for medication planning purposes.³

“We hope this opens the door to more patients with metastatic cancers to have precision medicine radiotherapy treatment options that leverage the biology of the tumor,” Williams said.

_REFERENCES:

_{1. City of Hope is the first cancer center in Southern California to offer patients novel targeted radiotherapy. News release. City of Hope. August 28, 2023. Accessed August 28, 2023. https://tinyurl.com/2brkz4kt}

_{2. RefleXion receives breakthrough device designation for lung cancer treatment. News release. RefleXion Medical, Inc. December 1, 2021. Accessed August 30, 2023. https://tinyurl.com/y4f6byth}

_{3. Prospective data registry and quality of life assessment of patients undergoing radiotherapy with the RefleXion Medical Radiotherapy System (PREMIER). ClinicalTrials.gov. Updated August 9, 2022. Accessed August 30, 2023. https://classic.clinicaltrials.gov/ct2/show/NCT05406167}